• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Biotech Investors Rolling the Dice with 250% SPAC Surge

cafead

Administrator
Staff member
  • cafead   Nov 14, 2020 at 02:02: PM
via Emerging biotech companies have been finding creative ways to explode onto the stock exchange during the COVID-19 pandemic. One of these is through special purpose acquisition companies (SPAC) mergers and acquisitions, which allow a desired company to go public more quickly and with less risk with than with the traditional Initial Public Offering (IPO).

article source